Zhejiang Xianju Pharmaceutical Co.,Ltd.

XSEC:002332 Stock Report

Market Cap: CN¥11.4b

Zhejiang Xianju PharmaceuticalLtd Past Earnings Performance

Past criteria checks 2/6

Zhejiang Xianju PharmaceuticalLtd has been growing earnings at an average annual rate of 13.3%, while the Pharmaceuticals industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 3.7% per year. Zhejiang Xianju PharmaceuticalLtd's return on equity is 9.9%, and it has net margins of 13.8%.

Key information

13.3%

Earnings growth rate

11.1%

EPS growth rate

Pharmaceuticals Industry Growth10.9%
Revenue growth rate3.7%
Return on equity9.9%
Net Margin13.8%
Last Earnings Update31 Mar 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Zhejiang Xianju PharmaceuticalLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

XSEC:002332 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Mar 244,2045811,307288
31 Dec 234,1235631,264261
30 Sep 234,1646921,289255
31 Mar 234,2887551,443251
01 Jan 234,3807491,536267
30 Sep 224,4936891,571237
30 Jun 224,4426761,597241
31 Mar 224,4056361,588249
01 Jan 224,3576191,560243
30 Sep 214,4026051,478232
30 Jun 214,3915731,472232
31 Mar 214,2765481,418232
31 Dec 204,0195051,335208
30 Sep 203,8734781,381228
30 Jun 203,6204421,307215
31 Mar 203,6184201,363210
31 Dec 193,7094101,430205
30 Sep 193,7413811,503169
30 Jun 193,7233521,497161
31 Mar 193,6283191,483146
31 Dec 183,6223011,474143
30 Sep 183,5142771,421124
30 Jun 183,3372491,313135
31 Mar 183,1162311,227107
31 Dec 172,8532071,13388
30 Sep 172,6711871,08847
30 Jun 172,5721681,0960
31 Mar 172,5471491,0890
31 Dec 162,5041461,0450
30 Sep 162,4571359620
30 Jun 162,5041239450
31 Mar 162,4411089000
31 Dec 152,4801078770
30 Sep 152,466888460
30 Jun 152,461718510
31 Mar 152,473608260
31 Dec 142,471577960
30 Sep 142,408458090
30 Jun 142,370387270
31 Mar 142,373516710
31 Dec 132,315616550
30 Sep 132,326786410
30 Jun 132,1941036240

Quality Earnings: 002332 has high quality earnings.

Growing Profit Margin: 002332's current net profit margins (13.8%) are lower than last year (17.6%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 002332's earnings have grown by 13.3% per year over the past 5 years.

Accelerating Growth: 002332's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: 002332 had negative earnings growth (-23%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-0.8%).


Return on Equity

High ROE: 002332's Return on Equity (9.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.